Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $18.39 USD
Change Today -1.29 / -6.55%
Volume 661.0K
PETX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Stuttgart
As of 8:10 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

aratana therapeutics inc (PETX) Snapshot

Open
$19.71
Previous Close
$19.68
Day High
$19.75
Day Low
$18.09
52 Week High
03/6/15 - $20.63
52 Week Low
10/2/14 - $9.20
Market Cap
642.0M
Average Volume 10 Days
575.7K
EPS TTM
$-1.20
Shares Outstanding
34.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARATANA THERAPEUTICS INC (PETX)

Related News

No related news articles were found.

aratana therapeutics inc (PETX) Related Businessweek News

View More BusinessWeek News

aratana therapeutics inc (PETX) Details

Aratana Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the licensing, development, and commercialization of biopharmaceutical products for the companion animals worldwide. Its product portfolio includes approximately 18 therapeutic candidates consisting of small molecule pharmaceuticals and large molecule biologics that target various opportunities in serious medical conditions in pets. The company develops AT-001, a prostaglandin E receptor 4 antagonist to treat the osteoarthritis pain in dogs, and degenerative joint disease in cats; AT-002, a ghrelin agonist for stimulation of appetite in dogs, as well as for weight gain in cats and dogs; AT-003, a bupivacaine liposome injectable suspension for the treatment of post-operative pain in cats and dogs; AT-004, a monoclonal antibody (MAB) used in the treatment of B-cell lymphoma in dogs; and AT-005, a caninized MAB for the treatment of T-cell lymphoma in dogs. It also develops other products, such as AT-006 for treatment of ocular lesions caused by feline herpes virus; AT-007 for the treatment of cats infected with feline immunodeficiency virus; AT-008, a small molecule for the treatment of canine lymphoma; AT-009, a caninized MAB used as an aid in the treatment of canine mast cell tumors; AT-010, a caninized MAB used as an aid for the treatment of atopic dermatitis in dogs; AT-011 to treat parvovirus in dogs; and AT-012 for treatment of feline calicivirus in cats. In addition, the company develops AT-015, a felinized MAB intended as an aid in the treatment of cat lymphoma; AT-016 that provides long-term relief of pain and disability caused by osteoarthritis through regeneration of joint damage; AT-017, a lymphoma immunotherapy for dog lymphoma; and AT-018, an oral CRTH2 antagonist for the treatment of atopic dermatitis. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Kansas City, Kansas.

49 Employees
Last Reported Date: 03/16/15
Founded in 2010

aratana therapeutics inc (PETX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $467.5K
Chief Financial Officer and Treasurer
Total Annual Compensation: $350.0K
Chief Development Officer
Total Annual Compensation: $302.5K
Chief Commercial Officer
Total Annual Compensation: $302.5K
Chief Scientific Officer
Total Annual Compensation: $321.9K
Compensation as of Fiscal Year 2014.

aratana therapeutics inc (PETX) Key Developments

Aratana Therapeutics, Inc. Announces Positive Pilot Field Study of AT-002 in Cats

Aratana Therapeutics, Inc. announced the positive results of a pilot field study of AT-002 (capromorelin) in cats. Capromorelin is a small molecule that mimics ghrelin, the naturally occurring hormone that stimulates appetite, increases body weight and increases serum growth hormone levels. The multi-site, placebo-controlled, pilot field study of approximately 40 cats measured weight gain/loss in cats with chronic kidney disease and documented weight loss who received AT-002 at a dose of 2 mg/kg compared to cats that received placebo treatment. Both groups were treated orally once daily for 90±3 days. Aratana also reported the results of a separate placebo-controlled laboratory study in 24 beagle dogs who received AT-002 once daily at 3 mg/kg or placebo once daily for 4 days.

Aratana Therapeutics, Inc. Provides Update on Development, Manufacturing and Commercialization of Monoclonal Antibodies (MAbs) Targeting Canine B-Cell Lymphoma (AT-004) and Canine T-Cell Lymphoma (AT-005)

Aratana Therapeutics, Inc. provided an update on the development, manufacturing and commercialization of their monoclonal antibodies (MAbs) targeting canine B-cell lymphoma (AT-004) and canine T-cell lymphoma (AT-005). AT-004 has received full licensure from the United States Department of Agriculture (USDA), and AT-005 has received conditional licensure from the USDA and Aratana continues to anticipate full licensure in 2015. The company has completed enrollment in its second multi-center, blinded, placebo-controlled, randomized study designed to assess adding AT-005 to a multi-agent chemotherapy protocol for dogs with T-cell lymphoma (T-LAB). In June 2015, the company completed enrollment in T-LAB with a total of approximately 60 client-owned dogs with intermediate to high grade T-cell lymphoma. In January 2015, the first study, T-CHOMP, was fully enrolled with a total of approximately 50 client-owned dogs. Results from both studies are expected by mid-2016. The company recently regained the commercialization and manufacturing rights for AT-004, and prior to July 2015, AT-004 had only been available in limited quantities for compassionate use. The company will be initiating an approximately 60 client-owned dog study in July 2015 to compare the effectiveness of two cycles of CHOP plus B-cell MAb against historical benchmarks for a standard of care CHOP protocol. The company expects to report the initial results of B-CEP and the mini B-CHOMP study results in mid-2016. The company anticipates that results from mini B-CHOMP will complement the three independent investigator initiated studies in other settings that have already been reported. After mini B-CHOMP is fully-enrolled, the company intends to make AT-004 available on a rolling regional basis as part of a B-cell Clinical Experience Program (B-CEP). Similar to the T-CEP program, the B-CEP program will allow a 30% discount on AT-004 in exchange for data associated with lymphoma treatments and outcomes. However, the company anticipates that it will remain manufacturing constrained on AT-004 until late-2016. In addition to the clinical studies, the company continues to conduct certain scientific studies with the MAbs. In particular, the company is working to better understand the specificity of its MAbs in an in-vivo setting.

Aratana Therapeutics, Inc. Announces Positive Pivotal Results for AT-003

Pacira Pharmaceuticals, Inc. announced positive results from its pivotal field effectiveness study of AT-003, the company's innovative drug for treating post-surgical pain in dogs. AT-003 is an extended-release bupivacaine liposome injectable suspension licensed from Pacira Pharmaceuticals, Inc. In the study, dogs receiving up to 5.3 mg/kg in a single dose of extended-release bupivacaine by infiltration during knee surgery demonstrated statistically significant improvements in pain evaluation compared to placebo (p<0.05). The study was a randomized, blinded, multicenter pivotal study conducted under protocol concurrence from the FDA'sCenter for Veterinary Medicine (CVM). Success criteria were based on pain evaluations at 24-hour intervals up to 72 hours after surgery, and AT-003 showed statistically significant higher success rates than placebo at each interval. The pivotal field effectiveness study data are the final piece of the Effectiveness Technical Section that Aratana plans to submit to the CVM as the Company pursues marketing approval for AT-003. Based on current timelines for the FDA approval process, Aratana anticipates commencing commercialization of AT-003 for dogs in 2016.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PETX:US $18.39 USD -1.29

PETX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Kindred Biosciences Inc $6.18 USD -0.07
View Industry Companies
 

Industry Analysis

PETX

Industry Average

Valuation PETX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 900.9x
Price/Book 3.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 782.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARATANA THERAPEUTICS INC, please visit www.aratana.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.